Show simple item record

dc.contributor.authorKoskan, Alexis
dc.contributor.authorBrennhofer, Stephanie A
dc.contributor.authorHelitzer, Deborah
dc.date.accessioned2020-08-03T19:42:47Z
dc.date.available2020-08-03T19:42:47Z
dc.date.issued2020-08
dc.identifier.citationKoskan, A., Brennhofer, S.A. & Helitzer, D. Administering the HPV Vaccine to People Living with HIV: Providers’ Perspectives. J Primary Prevent 41, 349–362 (2020). https://doi.org/10.1007/s10935-020-00598-wen_US
dc.identifier.issn0278-095X
dc.identifier.pmid32613520
dc.identifier.doi10.1007/s10935-020-00598-w
dc.identifier.urihttp://hdl.handle.net/10150/641979
dc.description.abstractHIV-positive patients suffer disproportionate burden of anal cancer, a disease which is primarily caused by persistent infection with human papillomavirus (HPV) and is potentially preventable with the completion of the HPV vaccine series. Past research qualitatively explored HIV-positive patients' perspectives about the HPV vaccine. However, little is known about their healthcare practitioners' vaccine recommendation behaviors, the strongest influence on vaccine uptake. This study reports on in-depth interviews conducted with 25 healthcare practitioners who provide care for HIV-positive patients. Qualitative themes that emerged from the study included clinicians' HPV vaccination behaviors, HIV patient's willingness to get the HPV vaccine, the role of HIV-positive patients' immune functioning in terms of timing of HPV vaccine administration, and vaccinating HIV-positive patients over age 26. The majority of providers offered the vaccine at their healthcare facility. Participants varied in their opinions related to the importance of patients' CD4 count in terms of timing of HPV vaccine administration; some believed that patients' immune functioning should first be stabilized to receive the most benefit from the vaccine series. They also differed in the perceived benefit of offering the vaccine to patients over age 26. In light of the U.S. Food and Drug Administration's recent approval to extend HPV vaccination to adults up to age 45 years, more HIV-positive adults may benefit by receiving this vaccine series. Future efforts should ensure that providers regularly promote the HPV vaccine to their adult HIV-positive patients. Vaccinating HIV-positive patients may help reduce the burden of HPV-related cancers, particularly anal cancer.en_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.rights© Springer Science+Business Media, LLC, part of Springer Nature 2020.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectanal canceren_US
dc.subjectHIV/AIDSen_US
dc.subjectHealthcare Practitionersen_US
dc.subjectHuman papillomavirus (HPV)en_US
dc.subjectQualitative researchen_US
dc.subjectvaccinationen_US
dc.titleAdministering the HPV Vaccine to People Living with HIV: Providers' Perspectivesen_US
dc.typeArticleen_US
dc.identifier.eissn1573-6547
dc.contributor.departmentUniv Arizona, Mel & Enid Zuckerman Coll Publ Hlthen_US
dc.identifier.journalJOURNAL OF PRIMARY PREVENTIONen_US
dc.description.note12 month embargo; published online: 1 July 2020en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal accepted manuscripten_US
dc.source.journaltitleThe journal of primary prevention
dc.source.volume41
dc.source.issue4
dc.source.beginpage349
dc.source.endpage362
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
HPV_Vaccine_Koskan_2020.pdf
Size:
289.8Kb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record